
COAG Stock Forecast & Price Target
COAG Analyst Ratings
Bulls say
Hemab Therapeutics Hldgs is supported by a de-risked lead asset in sutacimig, where FDA endorsement of the data package clears a path to a 2H26 pivotal Phase 3 in GT after Phase 2 LTE data in 34 participants showed sustained bleed reduction, a 62% drop in mean high-intensity ATBR, and no Grade >3 related events. The company’s second pillar, HMB-002, adds meaningful pipeline breadth with dose-proportionate PK/PD, ≥2.4-fold VWF and FVIII increases, normalization of thrombin generation and APTT, and 8/9 evaluable patients recording zero treated bleeds over 28 days, while HMB-003 expands optionality into heavy menstrual bleeding with differentiated once-per-cycle SC antifibrinolytic potential. Financially, Hemab ended 2Q26 with $457.5M in cash and equivalents against 2Q26 operating expenses of $26.1M and EPS of ($0.80), suggesting runway into 2030 while advancing multiple clinical catalysts.
Bears say
Hemab Therapeutics Hldgs is a clinical-stage biotechnology company whose valuation is highly exposed to binary development risk, with the biggest near-term concern being poorer-than-expected clinical results or failure of sutacimig, HMB-001, or HMB-002 to receive FDA approval in their respective indications. Because its pipeline is concentrated in prophylactic therapies for bleeding disorders such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease, setbacks in any one program could materially weaken the company’s fundamental outlook and limit commercial optionality. Competitive pressure from better-than-expected rival products and the possibility of unfavorable reimbursement further threaten future adoption and economics, making execution risk especially elevated for a company with no diversified operating base beyond research and development.
This aggregate rating is based on analysts' research of Hemab Therapeutics Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
COAG Analyst Forecast & Price Prediction
Start investing in COAG
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Hemab Therapeutics Holdings Inc (COAG) Forecast
COAG Analyst Forecast & Price Prediction
Start investing in COAG
Order type
Buy in
Order amount
Est. shares
0 shares